Apr 5, 2023 | Press Releases
INVO recently announced the signing of binding agreements to acquire this top-rated clinic SARASOTA, Fla. and MADISON, Wis., April 5, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility...
Mar 30, 2023 | Press Releases
SARASOTA, Fla., March 30, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and...
Mar 27, 2023 | Press Releases
SARASOTA, Fla., March 27, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and...
Mar 24, 2023 | Press Releases
SARASOTA, Fla., March 24, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and...
Mar 20, 2023 | Press Releases
Accretive acquisition expected to add significant scale to INVO’s operations Contributes over $5 million in incremental annual revenue as well as positive net income Initial transaction that establishes acquisitions as 3rd key aspect of INVO’s commercial...
Jan 5, 2023 | Press Releases
SARASOTA, Fla., Jan. 5, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the...
